Abstract
Purpose: The aim of this study was to evaluate the experience in pancreaticoduodenectomy in a low volume hospital for pancreatic resection. Patients and Methods: The hospital charts of the patients with periampullary and pancreatic head and neck cancer that underwent pancreaticoduodenectomy (group 1) or palliative surgical treatment (group 2) from January 1999 to December 2002 were retrospectively reviewed. Morbidity and mortality rates of the surgical procedures, and the patients' outcomes were evaluated. Kaplan-Meier method was used for survival analyses. Results: There were 22 patients in group 1 and 13 patients in group 2. The operative mortality and morbidity rates for group 1 were 13.6% and 34.6%, respectively. There was no operative mortality and/or morbidity in group 2. The median overall survival (OS) rate 41 months (%95 CI: 28-56) for group 1 and 6 months (%95 CI: 5-7) for group 2 (p<0.0001). Whereas 5-year overall survival was 76% (±0.09) in the first group, 6-months overall survival was 31% (±0.1) in the second group (p<0.0001). Conclusion: Although, pancreaticoduodenectomy has a higher mortality in low-volume hospitals for pancreatic resection, as in this study, it still remains the most effective treatment in periampullary and pancreatic head and neck cancers and improves the clinical outcome.
Keywords:
Periampullary cancer, pancreatic cancer, pancreaticoduodenectomy, mortality, survival
References
1
Van Geenen RCI, Van Gulik TM, Offerhaust GJA, de Wit LTh, Busch ORC, Obertop H, Gouma DJ. Survival after panvreaticoduodenectomy for periampullary adenocarcinoma: an update. EJSO 2001; 27: 549-557.
2
Riall TS, Cameron JL, LillemoeKD, Winter JM, Campbell KA, Hruban RH, Chang D, Yeo CJ. Resected periampullary adenocarcinoma: 5 year survivors and their 6- to 10-year follow-up. Surg 2006; 140: 764-772.
3
Brennan MF. Adjuvant therapy following resection for pancreatic adenocarcinoma. Surg Oncol Clin N Am 2004; 13: 555-566.
4
Zhu AX, Clark JW, Willett CG. Adjuvant therapy for pancreatic cancer: an evolving paradigm. Surg Oncol Clin N Am 2004; 13: 605-620.
5
Kausch W. Das Carcinom der Papilla duodeni und seine radikale Entfernung. Beitr Z Clin Chir 1912; 78: 439-486.
6
Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg 1935; 102: 763-779.
7
Crile G Jr. The advantages of bypass operations over radical pancreaticoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet 1970; 130: 1049-1053.
8
Rios G, Conrad A, Cole D, Adams D, Leveen M, O'Brien P, Baron P. Trends in indications and outcomes in the Whipple procedure over a 40-year period. Am Surg 1999; 65: 889-893.
9
Balcom JH, Rattner DW, Warshaw AL, Chang Y, Fernandez-del Castillo C. Ten-year experience with 733 pancreatic resections Changing indications, older patients, and decreasing length of hospitalization. Arc Surg 2001; 136: 391-398.
10
Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990's Pathology, complications, and outcomes. Ann Surg 1997; 226: 248-260.
11
Traverso LW, Shinchi H, Low D. Useful benchmarks to evaluate outcomes after esophagectomy and pancreaticoduodenectomy. Am J Surg 2004; 187: 604- 608.
12
Aranha GV, Hodul PJ, Creech S, Jacobs W. Zero mortality after 152 consecutive pancreaticoduodenectomies with pancreaticogastrostomy. J Am Coll Surg 2003; 197: 223-232.
13
Schmidt CM, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke EA, Wiesenauer CA, Baumgardner JA, Cummings OW, Jacobson LE, Broadie TA, Canal DF, Goulet RJ Jr, Curie EA, Cardenes H, Watkins JM, Loehrer PJ, Lillemoe KD, Madura JA. Pancreaticoduodenectomy A 20-Year experience in 516 patients. Arc Surg 2004; 139: 718-727.
14
Birkmeyer JD, Siewer AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE. Hospital volume and mortality in the United States. N Engl J Med 2002; 346: 1128-1137.
15
Ho V, Heslin MJ. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg 2003; 4: 509-514.
16
Metreveli RE, Sahm K, Abdel-Mısıh R, Petrelli NJ. Major pancreatic resections for suspected cancer in a communitybased teaching hospital: lessons learned. J Surg Oncol 2007; 95: 201-206.
17
Schwarz RE, Keny H, Ellenhorn JDI. A mortality-free decade of pancreatoduodenectoy: is quality independent of quantity? Am Surg1999; 65: 949-954.
18
Finlayson EV, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery: A national study. Arch Surg 2003; 138: 721-725.
19
Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280: 1747-1751.
20
Shrikhande SV, Qureshi SS, Rajneesh N and Shukla PJ. Pancreatic anastomoses after pancreaticoduodenectomy: Do we need further studies? World J Surg 2005; 29: 1642-1649.
21
Bassi C, Butturini G, Molinari E, Mascetta G, Salvia R, Falconi M, Gumbs A, Pederzoli P. Pancreatic fistula rate after pancreatic resection. The importance of definitions. Dig Surg 2004; 21: 54-59.
22
Papachristou DN, D'Agostino H, Fortner JG. Ligation of the pancreatic duct in pancreatectomy. Br J Surg 1980; 67: 260-262.
23
O'Neil S, Pickleman J, Aranha GV. Pancreaticogastrostomy following pancreaticoduodenectomy: review of 102 consecutive cases. World J Surg 2001; 25: 567-571.
24
Aston SJ, Longmire WP Jr. Management of the pancreas after pancreaticoduodenectomy. Ann Surg 1974; 179: 322-327.
25
Marcus SG, Cohen H, Ranson JHC. Optimal management of the pancreatic remnant after pancreaticoduodenectomy. Ann Surg 1995; 221: 635-648.
26
Roder JD, Stein HJ, Böttcher KA, Busch R, Heidecke CD, Siewert JR. Stented versus nonstented pancreaticojejunostomy after pancreatoduodenectomy: a prospective study. Ann Surg 1999; 229: 41-48.
27
Oussoultzoglou E, Bachellier P, Bigourdan JM, Weber JC, Nakano H, Jaeck D. Pancreaticogastrostomy decreased relaparotomy caused by pancreatic fistula after pancreaticoduodenectomy compared with pancreaticojejunostomy. Arch Surg 2004; 139: 327-335.
28
Aranha GV, Hodul P, Golts E, Oh D, Pickleman J, Creech S. A comparison of pancreaticogastrostomy and pancreaticojejunostomy following pancreaticoduodenectomy. J Gastrointest Surg 2003; 7: 672-682.
29
Yeo CJ, Cameron JL, Maher MM, Sauter PK, Zahurak ML, Talamini MA, Lillemoe KD, Pitt HA. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 1995; 222: 580-588.
30
Lermite E, Pessaux P, Brehant O, Teyssedou C, Pelletier I, Etienne S, Arnaud JP. Risk factors of pancreatic fistula and delayed gastric emptying after pancreaticoduodenectomy with pancreaticogastrostomy. J Am Coll Surg 2007; 204: 588-596.
31
Aranha GV, Aaron JM, Shoup M. Critical analysis of a large series of pancreaticogastrostomy after pancreaticoduodenectomy. Arch Surg 2006; 141: 574-580.
32
Jimenez RE, Fernandez-del Castillo C, Rattner DW, Chang Y, Warshaw AL. Outcome of pancreaticoduodenectomy with pylorus preservation or with antrectomy in the treatment of chronic pancreatitis. Ann Surg 2000; 23: 293-300.
33
Lin PW, Lin YJ. Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomy. Br J Surg 1999; 86: 603-607.
34
Patel AG, Toyama MT, Kusske AM, Alexander P, Ashley SW, Reber HA. Pylorus- preserving Whipple resection for pancreatic cancer. Is it any better? Arch Surg 1995; 130: 838-843.
35
van Berge Henegouwen MI, van Gulik TM, DeWit LT, Allema JH, Rauws EA, Obertop H, Gouma DJ. Delayed gastric emptying after standard pancreaticoduodenectomy versus pylorus-preserving pancreaticoduodenectomy: an analysis of 200 consecutive patients. J Am Coll Surg. 1997; 185: 373-379.
36
Horstmann O, Markus PM, Ghadimi MB, Becker H. Pylorus preservation has no impact on delayed gastric emptying after pancreatic head resection. Pancreas. 2004; 28: 69-74.
37
Wenger FA, Peter F, Zieren J, Steiert A, Jacobi CA, Müller JM. Prognosis factors in carcinoma of the head of the pancreas. Dig Surg. 2000; 17: 29-35.
38
Stojadinovic A, Brooks A, Hoos A, Jaques DP, Conlon KC, Brennan MF. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg. 2003; 196: 954-964.
39
Ni QX, Zhang QH, Fu DL, Cao GH, Yao QY, Jin C, Yu XJ, Zhang N, Zhang YL. Curative resection of pancreatic head carcinoma in recent 30 years: report of 377 cases. Hepatobiliary Pancreat Dis Int. 2002; 1: 126-128.
40
Sohn TA, Lillemoe KD, Cameron JL, Huang JJ, Pitt HA, Yeo CJ. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg. 1999;188:658-669.
41
Singh SM, Longmire WP Jr, Reber HA. Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg. 1990; 212: 132–139.
42
Warshaw AL, Gu ZY, Wittenberg J, Waltman AC. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg. 1990; 125: 230-233.
43
Taylor MC, McLeod RS, Langer B. Biliary stenting versus bypass surgery for the palliation of malignant distal bile duct obstruction: a meta-analysis. Liver Transpl 2000; 6: 302-308.
44
Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Coleman J, Pitt HA, Yeo CJ. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg. 1999; 230: 322-330.
45
The SSAT, AGA, AASLD, ASGE, AHPBA Consensus Panel. Management of unresectable pancreatic ductal cancer. J Gastrointest Surg 1999; 3: 331-332.
46
van Heek NT, van Geenen RC, Busch OR, Gouma DJ. Palliative treatment in “peri”- pancreatic carcinoma: stenting or surgical therapy? Acta Gastroenterol Belg. 2002; 65: 171-175.
47
van den Bosch RP, van der Schelling GP, Klinkenbijl JH, Mulder PG, van Blankenstein M, Jeekel J. Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas. Ann Surg. 1994; 219: 18-24.
48
van Heek NT, De Castro SM, van Eijck CH, van Geenen RC, Hesselink EJ, Breslau PJ, Tran TC, Kazemier G, Visser MR, Busch OR, Obertop H, Gouma DJ. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg. 2003; 238: 894-905.
49
Nieveen van Dijkum EJ, Romijn MG, Terwee CB, de Wit LT, van der Meulen JH, Lameris HS, Rauws EA, Obertop H, van Eyck CH, Bossuyt PM, Gouma DJ. Laparoscopic staging and subsequent palliation in patients with peripancreatic carcinoma. Ann Surg. 2003; 237: 66-73.
50
van der Schelling GP, van den Bosch RP, Klinkenbij JH, Mulder PG, Jeekel J. s there a place for gastroenterostomy in patients with advanced cancer of the head of the pancreas? World J Surg. 1993; 17: 128-33.
51
Egrari S, O'Connell TX. Role of prophylactic gastroenterostomy for unresectable pancreatic carcinoma. Am Surg. 1995; 61: 862-4.
